作者: Katharigatta N. Venugopala , Christophe Tratrat , Melendhran Pillay , Fawzi M. Mahomoodally , Subhrajyoti Bhandary
DOI: 10.3390/ANTIBIOTICS8040247
关键词: In vitro 、 Chemistry 、 Rifampicin 、 Mycobacterium tuberculosis 、 In silico 、 DNA 、 Isoniazid 、 Enzyme 、 Molecular biology 、 Minimum inhibitory concentration
摘要: Novel series of diversely substituted indolizines were designed, synthesized, and evaluated for their in vitro anti-mycobacterial activity against H37Rv multi-drug-resistant (MDR) strains Mycobacterium tuberculosis (MTB). Many compounds exhibited significant inhibitory MTB strains. Indolizines 2d, 2e, 4 also found to be active clinical isolates with multi-resistance rifampicin isoniazid. Indolizine was identified as the most promising agent, displaying minimum concentration (MIC) values 32 μg/mL MDR strains, respectively. Furthermore, an silico study carried out prospective molecular target identification revealed favorable interactions enzymes CYP 121, malate synthase, DNA GyrB ATPase. None potent molecules presented toxicity peripheral blood mononuclear (PBM) cell lines, demonstrating potentiality used drug-sensitive drug-resistant therapy.